Chemo-immunotherapy before surgery for bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have bile duct cancer that has not spread beyond the local area and is considered advanced but still removable with surgery.
- You should not have had any previous cancer treatments like chemotherapy, radiation, or local ablation.
- You need to be in generally good health, able to do daily activities (ECOG 0 or 1), and have adequate organ function (kidneys, liver, blood counts).
- You must not have active autoimmune diseases (except some controlled conditions), active infections like hepatitis or HIV, or have had an organ transplant.
- You must be willing to use effective birth control during the study and for 3–6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a specific chemotherapy after surgery for people with stage II or III bile duct, gallbladder, or ampullary cancer. It may help reduce the chance of cancer coming back.
This trial tests a combination of immunotherapy (tislelizumab) and chemotherapy (gemcitabine, cisplatin, S-1) given before surgery for patients with bile duct cancer that is high-risk for return or has come back within 6 months after a prior surgery. The goal is to see if this treatment can improve outcomes.
This trial tests whether receiving chemotherapy (cisplatin, gemcitabine, and nab-paclitaxel) before surgery can improve outcomes for people with high-risk bile duct or gallbladder cancer. It compares this approach to going straight to surgery.
This trial tests a new combination of immunotherapy (tislelizumab), radiation, and chemotherapy before surgery for people with bile duct cancer that is hard to remove. The goal is to shrink the tumor enough to allow successful surgery.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
Hear when a new Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.